Scientists from Tel Aviv University and the Israel Institute of Biological Research say their vaccine uses lipid ...

New bacterial mRNA vaccine technology shows promise in fighting plague, and could help address the global threat of ...

TAU’s vice president for research and development said that they worked on the project for two-and-a-half years and were very ...

Lexington, Massachusetts Tuesday, July 22, 2025, 18:00 Hrs [IST] ...

Potential Positives. Voyager Therapeutics will present significant advancements in their tau silencing gene therapy VY1706, which has achieved up to 73% knockdown of tau mRNA in non-human primates ...

In preclinical non-human primate (NHP) studies, a single IV administration of VY1706 was well-tolerated and resulted in dose-dependent knockdown of tau mRNA (44% to 73%) and tau protein (27% to 55 ...

Scientists at The Florey have developed an mRNA technology approach to target the toxic protein tau, which builds up in patients with Alzheimer’s disease and other dementias. To date, mRNA has ...

--Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has selected a lead development candidate, VY1706, for its tau ...

Nevertheless, the scientists studied the potential effects of this tau by creating induced microglia-like cells, i.e., iMGLs, from iPSCs of two people who each carried one copy of the MAPT IVS10+16 ...

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study ...